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Background/Aims. Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease that can progress to cirrhosis and
hepatocellular carcinoma. This retrospective chart review investigated the incidence of hepatic steatosis in London, Ontario,
Canada. Methods. A retrospective chart review was performed on emergency room (ER) patients undergoing nonscheduled
computed tomography (CT) imaging over a six-month period in London, Ontario. CT images and reports were examined to
determine presence of steatosis. Analyses of the electronic chart for a period of six months following the CT and communication
with the patients’ family doctors were used to determine if there was follow-up. Waist circumference, subcutaneous fat depth, and
abdominal fat volumes were calculated. Results. 48/450 patients meeting inclusion criteria were identified by radiology as having
steatosis, with 34/40 (85%) family physicians unaware of the finding. 24.7% (100/405) of patients met standard CT criteria for
steatosis, 40 of which were reported by the radiologist. Waist circumference, subcutaneous adipose tissue depth, subcutaneous
adipose tissue volume, and visceral adipose tissue volume were significantly associated with steatosis. Conclusions. The hepatic
steatosis prevalence we report is the first reported in a Canadian population. Early identification of steatosis will become more
important as new pharmacologic therapies arise.

1. Introduction
With the rapidly growing prevalence of obesity throughout the world [1], morbidity and mortality related to its
complications are on the rise [2]. As obesity rates continue
to rise in North America, nonalcoholic fatty liver disease
(NAFLD) has become an epidemic. NAFLD has a spectrum
of disease severity, from simple steatosis to steatohepatitis,
with potential progression to fibrosis and cirrhosis [3, 4].
A small portion of patients with cirrhosis will develop

hepatocellular carcinoma [5]. The frequency of liver transplantation for patients with NAFLD-related cirrhosis has
increased fivefold over the last ten years [6]. NAFLD-related
cirrhosis is currently the second most common indication
for liver transplantation and is projected to become the most
common indication for liver transplantation by 2020 [6].
Establishing a definitive diagnosis of NAFLD requires
both clinical and histologic data. However, a minority of
patients receive parenchymal liver biopsies. Instead, the
combination of patient history, physical examination, blood
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test results, and radiologic findings is used to exclude other
causes of liver disease. Imaging studies support the diagnosis.
CT diagnostic criteria for steatosis are liver attenuation at
least 10 Hounsfield Units (HU) less than that of the spleen
or absolute liver attenuation of less than 40 HU. Unenhanced
CT has a sensitivity for steatosis ranging from 43 to 95% and
a specificity of 90–100% [7, 8]. Sensitivity rises to 93% for
detecting steatosis involving greater than 33% of the liver,
with positive predictive value of 76% [9]. With contrastenhanced CT, a difference of 18.5 HU between liver and
spleen attenuation had a sensitivity of 93%, a specificity of
93%, and a receiving operating curve of 0.98 [10]. The sensitivity and specificity of unenhanced CT are similar to those
of ultrasound (SN 84.8%, SP 93.6%) and Magnetic Resonance
Imaging (SN 81%, SP 100%) [7, 8].
Visceral abdominal tissue (VAT) is associated with cardiovascular disease [11–13] and its risk factors, including diabetes mellitus [14–16], insulin resistance [15, 17, 18], hypertension [19–21], dyslipidemia [22–24], and metabolic syndrome
[11–13, 25]. NAFLD is closely tied to metabolic syndrome,
diabetes mellitus type 2, and cardiovascular disease [26, 27].
Visceral fat, which releases portal free fatty acids and secretes
adipokines, particularly adiponectin, is central to NAFLD’s
pathophysiology [28].
The aim of the current study was to determine the
prevalence of hepatic steatosis, determine the follow-up of
the incidental finding of hepatic steatosis, and characterize
the accuracy of radiologic reporting of hepatic steatosis.
Furthermore, we aimed to determine an association between
steatosis and quantitative measures of waist circumference
and abdominal adipose tissue.

2. Methods
2.1. Study Subjects. A retrospective chart review was performed on all computed tomography (CT) Scans of the
thorax, abdomen, and pelvis performed at the London Health
Science Centre (LHSC) during “on-call” hours (between the
hours of 5:00 pm and 8:00 am, Monday to Friday, and
between 8 am and 8 am, Saturday and Sunday) between
January 1, 2011, and July 31, 2011. Patients were excluded if
the CT was scheduled in advance, if the indication was for
elevated liver enzymes or known liver pathology, and if the
patient was admitted to hospital following the CT Scan. The
CT studies obtained during “on-call” hours were used as
there was a readily available database with focused clinical
history and exam findings. Patients had to be undergoing
imaging for a primary complaint felt to be independent of
liver pathology, as to provide a representative sample of the
general population. Patients were required to be local residents of London, Ontario, Canada, to ensure documentation
of follow-up was complete.
2.2. Determination of the Incidental Findings of Fatty Liver
Disease and Patient Liver Function. The official, signed electronic radiology reports were screened for incidental findings
of fatty liver disease. Patients who were reported to have
fatty liver disease on their ER CT had an electronic chart
review performed, documenting ER bloodwork, including
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alanine aminotransferase (ALT), aspartate aminotransferase
(AST), alkaline phosphatase (ALP), gamma glutamyl transferase (GGT), bilirubin, platelet count, and International
Normalized Ratio (INR).
2.3. Follow-Up Assessment of Patients with Incidental Findings
of Fatty Liver Disease. The electronic charts of patients
having incidental findings of fatty liver disease were reviewed
to assess patient follow-up of fatty liver disease. Patient
follow-up was considered to have occurred if there was any
consult made to either the family physician or a specialist
to further assess and manage the patient’s possible fatty liver
disease.
The family physicians of patients who were reported
to have the incidental finding of fatty liver disease were
contacted via phone to determine if follow-up had been
arranged. Phone attempts were made until follow-up was
determined.
2.4. Measurement of Liver and Spleen Attenuation. CT criteria for steatosis on non-intravenous contrast scans included
the following: liver attenuation 10 HU less than the spleen
attenuation, absolute liver attenuation of less than 40 HU,
and liver-to-spleen attenuation ratio less than 1 [7, 8]. An
example of liver and spleen attenuation measurement is
shown in Figure 1. CT Pulmonary Angiograms have images
with intravenous contrast in the early arterial phase and it
was considered a noncontrast CT Scan for the purposes of
steatosis analysis. CT criteria for steatosis with intravenous
contrast in the venous phase included liver attenuation 20 HU
less than spleen attenuation [10]. CT Scans with intravenous
contrast in the arterial phase or with heterogenous spleen
attenuation were excluded. Liver attenuation was a mean of
four measurements in areas 5 and 6. Spleen attenuation was a
mean of a posterior and an anterior measurement.
2.5. Measurement of Abdominal Adipose Tissue. Waist circumference and subcutaneous fat depth were measured on
the abdominal CT Scans. Waist circumference was measured
at the level of the umbilicus. In scans where portion of the
abdomen was outside of the image field, the contour of the
waist circumference was estimated with a continuous arc. The
subcutaneous fat depth was measured at three points: right
and left midclavicular lines at the level of the umbilicus, as
well as suprapubically at the level of iliac crest. The mean of
these three values was calculated.
Semiautomated segmentation was performed on all
patients using an adaptation of a previously validated method
for fat distribution imaging [29]. CT images were loaded
into the software by a trained observer and a subset of slices
were selected for segmentation and volume measurement.
For each patient, the superior boundary volume was selected
as the axial slice where the dome of the liver was first visible
and the inferior boundary where the top of the femoral heads
was visible. Full volume adipose tissue was identified as any
tissue within −205 to −25 HU range. Partial volume adipose,
which was classified as tissue between −25 and 0 HU range
and located on the boundary of full volume adipose, was also
included as adipose. After tissue identification, adipose tissue
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Figure 1: CT images showing an example of steatosis (a) and a nonsteatotic liver (b). Hounsfield Units are indicated in the circles.
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Figure 2: Reconstructed CT images demonstrating SAT (a) and VAT (b) volumes, as well as abdominal musculature (c). Muscle (red), lungs
(blue), and bone (white) are also seen.

was segmented into subcutaneous and visceral volumes, as
shown in Figure 2. Nonvisceral adipose structures such as
paravertebral and intermuscular were removed by a trained
observer using tools available with the software. Finally, all
pixels in the segmented adipose volumes were summed and
converted to spatial volumes (cm3 ).
Two-tailed 𝑡-tests were performed using Excel for Mac
2011, version 14.4.1 (Microsoft). Statistics were performed
using IBM SPSS statistics 2.0.

3. Results
3.1. Incidental Finding of Fatty Liver Disease. Over a 6-month
period from January to July 2011, 1259 CT Scans of the thorax,
abdomen, and pelvis were performed at the London Health
Science Centre’s (LHSC) Emergency Department (ED), of
which 450 (35.7%) met the inclusion criteria. The 450 patients
were comprised of 223 female and 227 male patients, with a

mean age of 58.0 ± 18.2 (range 18–95) years. Of those 450
patients, the reading radiologists documented 48 patients
(10.7%) as having the incidental finding of fatty liver disease.
The 48 patients included 19 female and 29 male patients, with
a mean age of 54.1 ± 13.9 (range 24–78) years.
Electronic chart reviews were performed on the 48
patients who had the incidental finding of fatty liver disease, to determine follow-up and assess initial blood work
drawn during their emergency room visit (Table 1). Sixtyseven percent (𝑁 = 12/18) had elevated levels of alanine
aminotransferase (ALT; normal < 33 units/L; range 9–64
units/L; mean 39 ± 17 units/L). Aspartate aminotransferase
(AST; normal < 32 units/L) was elevated in 32% of patients
(𝑁 = 8/25; mean 30 ± 12 units/L; range 10–63). Alkaline
phosphatase (ALP; normal 35–104 units/L) was elevated in
4 of 27 patients (15%; mean 76 ± 26; range 38–129). Two of
6 patients (33%) had elevated gamma glutamyl transferase
(GGT; normal < 61 units/L; mean 68 ± 58 units/L; range
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Table 1: Blood work performed during the Emergency Department
visit of the 48 patients with the incidental finding of fatty liver.

ALT (normal < 33)
𝑁 = 18
AST (normal < 32)
𝑁 = 25
ALP (normal 35–104)
𝑁 = 27
GGT (normal < 61)
𝑁=6
INR (normal 0.9–1.1)
𝑁 = 32
PTT (normal 25–39)
𝑁 = 32
Platelet (normal
150–400)
𝑁 = 48

AVG ± SD

Range

39 ± 17

9–64

30 ± 12

10–63

76 ± 26

38–129

68 ± 58

12–153

1.1 ± 0.1

0.8–1.3

29 ± 2

23–36

233 ± 62

104–360

Abnormal
values
67%
𝑁 = 12
32%
𝑁=8
15%
𝑁=4
33%
𝑁=2
13%
𝑁=4
0%
𝑁=0
4%
𝑁=2

12–153). Two of 48 patients (4%) had abnormal platelet
counts (normal 150–400; mean 233 ± 62; range 104–360).
Partial thromboplastin time (PTT; normal 25–39 seconds)
and International Normalized Ratio (INR; normal 0.9–1.1)
were increased in 0 of 32 (0%; mean 29±2; range 23–36) and 4
of 32 (13%; mean 1.1±0.1; range 0.8–1.3) patients, respectively.
3.2. Follow-Up of Patients with Fatty Liver Disease. Oneyear follow-up was assessed via electronic chart review
and contact with the patient’s family physician. None of
the 48 patients with incidental findings of fatty liver had
any subsequent documented follow-up bloodwork, imaging,
testing, or clinic visits in the one year following their initial
CT finding of fatty liver disease.
The family physicians of the 48 patients with incidental
findings of fatty liver were contacted via telephone to determine if they were aware of the result of the LHSC ER CT
Scan. We were unable to contact two of the 48 (4%) family
physicians despite repeated attempts. Of the remaining 46
patients, 6 patients (13%) had no family physician and 34
patients (74%) had family physicians who were unaware. Six
of the 46 patients (13%) had family physicians who were aware
of the CT results; however none of the family physicians
had performed further investigations or management of the
finding.
3.3. Prevalence of Steatosis. Forty-five (2 with reported fatty
liver disease and 43 without reported fatty liver disease) of
the 450 patients were excluded from the HU analysis as the
CT Scans had intravenous contrast visualized in the arterial
phase. Of the remaining CT Scans, 168 had no intravenous
(IV) contrast used, 44 had IV contrast visualized in the
early arterial phase, and 193 had IV contrast visualized in
the venous phase. One hundred of the 405 included patients
(24.7%) met CT criteria for steatosis. Of the 46 patients
with fatty liver disease reported by the radiologist who were
included in the HU analysis, 40 patients (87.0%) fulfilled

criteria for steatosis and 6 patients (13.0%) did not. Sixty
of 359 patients (16.7%) without reported fatty liver disease
met CT criteria for steatosis. A radiologist report of the
incidental finding of fatty liver disease had a sensitivity of
40%, specificity of 98%, positive predictive value of 0.87,
negative predictive value of 0.83, positive likelihood ratio of
20.3, and negative likelihood ratio of 0.6 when compared to
CT criteria for steatosis.
3.4. Association of Steatosis with Waist Circumference and
Abdominal Adipose Tissue. Waist circumference, as measured on CT, was significantly larger in patients with incidental finding of steatosis (𝑁 = 46) as compared with a cohort of
patients with no reported steatosis (𝑁 = 97) (113.6 ± 11.4 cm
versus 99.1 ± 13.9 cm, 𝑃 < 0.001). Right periumbilical (38.8 ±
4.4 mm versus 24.5 ± 10.7 mm, 𝑃 < 0.001), left periumbilical
(38.8 ± 4.2 mm versus 24.1 ± 10.7 mm, 𝑃 < 0.001), suprapubic
(38.0 ± 6.2 mm versus 25.0 ± 11.6 mm, 𝑃 < 0.001), and
mean (34.3 ± 12.5 mm versus 24.4 ± 11.0 mm, 𝑃 < 0.001)
subcutaneous fat depth were significantly larger in patients
with steatosis (𝑁 = 46) versus a cohort of those without
steatosis (𝑁 = 98).
Two hundred and ninety-four patients had complete
abdominal CT Scans available for measurement of adipose
tissue volumes. Compared with patients who did not meet CT
criteria for steatosis (𝑁 = 215), patients meeting CT criteria
for steatosis (𝑁 = 79) had significantly greater abdominal
subcutaneous adipose tissue (SAT) volume (13,726 ± 7,691
versus 9,863 ± 5,686 cm3 , 𝑃 < 0.0001), abdominal visceral
adipose tissue (VAT) volume (9546 ± 5773 versus 6,644 ±
4,464 cm3 , 𝑃 < 0.0001), and total abdominal tissue (TAT)
volume (23,349 ± 11,878 versus 18,071 ± 21,921 cm3 , 𝑃 = 0.04).
Linear regression comparing abdominal adipose tissue
volumes with liver attenuation (Hounsfield Units) demonstrated a significant association with VAT (accounting for
26% of variation in liver attenuation; 𝑃 < 0.001), SAT
(accounting for 62% of variation, 𝑃 < 0.001), and TAT
(accounting for 47% of variation, 𝑃 < 0.001).

4. Discussion
This study is the first to report Canadian prevalence of hepatic
steatosis. With 24.7% of patients meeting CT criteria for
steatosis, our study is above the global average of 20% [30]
but below reported prevalence of 33.6% in the United States
of America [31]. Canada does have a lower obesity rate than
the United States of America [32] and thus rates of steatosis
in Canada would be expected to be lower. This study provides
an interesting Canadian perspective on the prevalence of
steatosis.
Our study also demonstrates poor follow-up of an incidental finding of steatosis. Other studies have shown lack of
follow-up of concerning incidental findings discovered on ER
CT Scans in patients seen for renal colic and trauma [33, 34].
The lack of follow-up of steatosis in this study represents a
missed opportunity to intervene earlier with these patients,
as recommendations are clear on the evaluation of patients
with incidentally discovered hepatic steatosis [35]. Guidelines
recommend that patients with hepatic steatosis incidentally
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detected on imaging should be evaluated as though they
have suspected NAFLD and worked up accordingly if they
have symptoms or signs attributable to liver disease or have
abnormal liver biochemistries (Strength 1, Evidence A) [35].
Twelve of the 18 (67%) patients with incidentally discovered
steatosis who had liver enzymes drawn had an abnormal
ALT, with their family doctor being aware of the incidentally
found steatosis in only 3 (2 with normal ALT and 1 with
abnormal ALT) of the 12 patients. Guidelines also recommend that, in patients with unsuspected hepatic steatosis in
whom steatosis is incidentally detected on imaging and who
lack any liver-related symptoms or signs and have normal
liver biochemistries, it is reasonable to assess metabolic risk
factors (e.g., obesity, glucose intolerance, and dyslipidemia)
and alternate causes for hepatic steatosis such as significant
alcohol consumption or medications (Strength 1, Evidence
A) [35]. Regarding patients with normal liver enzymes and
incidentally discovered steatosis, very few family physicians
were aware of the incidental finding of steatosis (2 of 7
with normal ALT, 4 of 16 with normal AST, 3 of 23 with
normal ALP, and 1 of 4 with a normal GGT) and no family
physician was aware of guidelines for specific follow-up of
these patients.
We show a significant relationship with waist circumference, visceral and subcutaneous fat measurements, and liver
steatosis. One of the main limitations of diagnosing steatosis
on CT is the inability to determine if the steatosis is reactive
to infectious or inflammatory conditions, such as hepatitis
or alcohol induced or secondary to metabolic syndrome.
Although this correlation between fatty liver and increase in
visceral and subcutaneous fat does not exclude confounding
etiology, it certainly adds support to the hypothesis that
visceral fat is central to the pathophysiology of NAFLD.
Radiologists significantly underreported the presence of
steatosis on CT. Radiologists only reported 40% of the
patients who met criteria for steatosis (for every patient correctly reported as having steatosis, there were 1.5 patients with
steatosis that were unreported). Failing to report steatosis
on CT is a missed opportunity to intervene in the lives
of these patients. There were also six of the 46 patients
reported to have steatosis who did not meet criteria for
steatosis. Misdiagnosis of potential liver disease may have
consequences, such as unnecessary parenchymal biopsies.
There are limitations to this study that must be taken
into account when interpreting the results. There may be
selection bias in the inclusion of the patients as patients
who present to the ER during “on-call” hours may not be
representative of the general population. As in any retrospective observational study, there may have been unmeasured confounders. We have no information on medications,
diet, stress levels, physical activity, medical comorbidities,
or other medical history or physical exam history. CT has
difficulty differentiating between steatosis and steatohepatitis,
as well as nonalcoholic fatty liver disease and nonalcoholic
steatohepatitis. No histology is available to compare with
CT findings. Although NAFLD is the most common cause
of steatosis, there are other causes that we cannot exclude,
including alcoholic liver disease (defined as >21 drinks per
week for men and >14 drinks per week for women over at least
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a two-year period), hepatitis C (particularly genotype 3), and
other less common causes of steatosis [35]. Pregnancy-related
liver disease is ruled out, as patients are required to declare
if they are pregnant and to have a negative 𝛽-HCG prior to
CT. However, steatosis seen on imaging (no matter the cause)
requires investigation and follow-up [35].
In summary, our findings suggest that 10.7% of patients
receiving CT Scans in the ER have incidental findings of
steatosis reported by the radiologist and that follow-up of
these reports is lacking. Twenty-five percent of patients met
CT criteria for steatosis, providing an estimate of the Canadian prevalence. Lack of follow-up of incidental findings of
steatosis represents a missed opportunity for early detection
and intervention to prevent further complications. More
research is required to further characterize and understand
the potential long term impact of recognition and follow-up
of hepatic steatosis identified in this setting on the progression and outcome of the disease. Improving the knowledge
among family physicians of this condition, its associated
risk factors, and its management is important in identifying
patients who require further investigations and management.
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